방광암 치료제 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2024-2034년)
Bladder Cancer Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034
상품코드:1508422
리서치사:Transparency Market Research
발행일:2024년 05월
페이지 정보:영문 136 Pages
라이선스 & 가격 (부가세 별도)
한글목차
방광암 치료제 시장 - 조사 범위
TMR의 조사 보고서 "세계의 방광암 치료제 시장"은 2024년부터 2034년까지 예측 기간 동안 시장 지표에 대한 귀중한 통찰력을 얻기 위해 과거뿐만 아니라 현재의 성장 동향과 기회를 조사했습니다. 이 보고서는 2024년을 기준연도로, 2034년을 예측 연도로 하여 2018년부터 2034년까지의 세계 방광암 치료제 시장의 수익과 예측을 제공합니다. 또한 2024년부터 2034년까지 세계 방광암 치료제 시장의 연평균 복합 성장률(CAGR%)도 제시합니다.
이 보고서는 광범위한 조사를 통해 작성되었으며, 1차 조사에서 분석가들은 KOL(Key Opinion Leader), 업계 리더 및 오피니언 제조업체를 인터뷰하고, 2차 조사에서는 주요 기업의 제품 자료, 연례 보고서, 보도 자료, 관련 자료 등을 참조하여 방광암 치료제 시장을 이해했습니다,
시장 현황
2023년 시장 규모
2억 7,140만 달러
2034년 시장 규모
4억 5,630만 달러
CAGR
4.8%
이 보고서는 세계 방광암 치료제 시장의 경쟁 환경을 조사했습니다. 세계 방광암 치료제 시장에서 활동하는 주요 기업들이 확인되었으며, 각 기업들은 다양한 속성별로 프로파일링되었습니다. 기업 개요, 재무 상태, 최근 동향, SWOT 등은 이 보고서에서 다루는 세계 방광암 치료제 시장 기업의 속성입니다.
목차
제1장 서문
제2장 전제조건과 조사 방법
제3장 주요 요약
제4장 시장 개요
서론
개요
시장 역학
세계 시장 분석과 예측, 2020-2034년
제5장 주요 인사이트
파이프라인 분석
주요 제품/브랜드 분석
주요 M&A
COVID-19의 산업에 대한 영향
제6장 세계 시장 분석과 예측 : 치료 유형별
서론과 정의
주요 조사 결과와 발전
시장 매출 예측 : 치료 유형별, 2020-2034년
화학요법
면역치료
표적치료
수술
방사선치료
기타(병용요법 등)
시장의 매력 : 치료 유형별
제7장 세계 시장 분석과 예측 : 방광암 유형별
서론과 정의
주요 조사 결과와 발전
시장 매출 예측 : 방광암 유형별, 2020-2034년
비근층 침윤성 방광암(NMIBC)
근층 침윤성 방광암(MIBC)
시장의 매력 : 방광암 유형별
제8장 세계 시장 분석과 예측 : 투여 경로별
서론과 정의
주요 조사 결과와 발전
시장 매출 예측 : 투여 경로별, 2020-2034년
경구
정맥내
방광내
시장의 매력 : 투여 경로별
제9장 세계 시장 분석과 예측 : 최종사용자별
서론과 정의
주요 조사 결과와 발전
시장 매출 예측 : 최종사용자별, 2020-2034년
병원
전문 클리닉
외래수술센터(ASC)
암연구기관
시장의 매력 : 최종사용자별
제10장 세계 시장 분석과 예측 : 지역별
주요 조사 결과
시장 매출 예측 : 지역별, 2020-2034년
북미
유럽
아시아태평양
라틴아메리카
중동 및 아프리카
시장의 매력 : 지역별
제11장 북미 시장 분석과 예측
제12장 유럽 시장 분석과 예측
제13장 아시아태평양 시장 분석과 예측
제14장 라틴아메리카 시장 분석과 예측
제15장 중동 및 아프리카 시장 분석과 예측
제16장 경쟁 구도
시장 기업 - 경쟁 매트릭스(기업 Tier 및 규모별)
시장 점유율 분석 : 기업별(2023년)
기업 개요
Merck & Co., Inc.
Bristol-Myers Squibb Company
F. Hoffmann-La Roche AG
AstraZeneca
Johnson & Johnson
Pfizer Inc.
Novartis AG
Eli Lilly and Company
Sanofi S.A.
Genentech, Inc.
LSH
영문 목차
영문목차
Bladder Cancer Therapeutics Market - Scope of Report
TMR's report on the global bladder cancer therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global bladder cancer therapeutics market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global bladder cancer therapeutics market from 2024 to 2034.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the bladder cancer therapeutics market.
Market Snapshot
Market Value in 2023
US$ 271.4 Mn
Market Value in 2034
US$ 456.3 Mn
CAGR
4.8%
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global bladder cancer therapeutics market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global bladder cancer therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global bladder cancer therapeutics market.
The report delves into the competitive landscape of the global bladder cancer therapeutics market. Key players operating in the global bladder cancer therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global bladder cancer therapeutics market profiled in this report.
Key Questions Answered in Global bladder cancer therapeutics Market Report:
What is the sales/revenue generated by bladder cancer therapeutics across all regions during the forecast period?
What are the opportunities in the global bladder cancer therapeutics market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2034?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?
Bladder Cancer Therapeutics Market - Research Objectives and Research Approach
The comprehensive report on the global bladder cancer therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global bladder cancer therapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global bladder cancer therapeutics market.
Table of Contents
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Bladder Cancer Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Bladder Cancer Therapeutics Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Bladder Cancer Therapeutics Market Analysis and Forecast, by Type of Treatment
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Type of Treatment, 2020-2034
6.3.1. Chemotherapy
6.3.2. Immunotherapy
6.3.3. Targeted Therapy
6.3.4. Surgery
6.3.5. Radiation Therapy
6.3.6. Others (Combination Therapy, etc.)
6.4. Market Attractiveness, by Type of Treatment
7. Global Bladder Cancer Therapeutics Market Analysis and Forecast, by Type of Bladder Cancer
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Type of Bladder Cancer, 2020-2034
7.3.1. Non-Muscle Invasive Bladder Cancer (NMIBC)
7.3.2. Muscle Invasive Bladder Cancer (MIBC)
7.4. Market Attractiveness, by Type of Bladder Cancer
8. Global Bladder Cancer Therapeutics Market Analysis and Forecast, by Route of Administration
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Route of Administration, 2020-2034
8.3.1. Oral
8.3.2. Intravenous
8.3.3. Intravesical
8.4. Market Attractiveness, by Route of Administration
9. Global Bladder Cancer Therapeutics Market Analysis and Forecast, by End-user
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by End-user, 2020-2034
9.3.1. Hospitals
9.3.2. Specialty Clinics
9.3.3. Ambulatory Surgical Centers
9.3.4. Cancer Research Institutes
9.4. Market Attractiveness, by End-user
10. Global Bladder Cancer Therapeutics Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2020-2034
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Region
11. North America Bladder Cancer Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Type of Treatment, 2020-2034
11.2.1. Chemotherapy
11.2.2. Immunotherapy
11.2.3. Targeted Therapy
11.2.4. Surgery
11.2.5. Radiation Therapy
11.2.6. Others (Combination Therapy, etc.)
11.3. Market Attractiveness, by Type of Treatment
11.4. Market Value Forecast, by Type of Bladder Cancer, 2020-2034
11.4.1. Non-Muscle Invasive Bladder Cancer (NMIBC)
11.4.2. Muscle Invasive Bladder Cancer (MIBC)
11.5. Market Attractiveness, by Type of Bladder Cancer
11.6. Market Value Forecast, by Route of Administration, 2020-2034
11.6.1. Oral
11.6.2. Intravenous
11.6.3. Intravesical
11.7. Market Attractiveness, by Route of Administration
11.8. Market Value Forecast, by End-user, 2020-2034
11.8.1. Hospitals
11.8.2. Specialty Clinics
11.8.3. Ambulatory Surgical Centers
11.8.4. Cancer Research Institutes
11.9. Market Attractiveness, by End-user
11.10. Market Value Forecast, by Country/Sub-region, 2020-2034
11.10.1. U.S.
11.10.2. Canada
11.11. Market Attractiveness Analysis
11.11.1. By Type of Treatment
11.11.2. By Type of Bladder Cancer
11.11.3. By Route of Administration
11.11.4. By End-user
11.11.5. By Country
12. Europe Bladder Cancer Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Type of Treatment, 2020-2034
12.2.1. Chemotherapy
12.2.2. Immunotherapy
12.2.3. Targeted Therapy
12.2.4. Surgery
12.2.5. Radiation Therapy
12.2.6. Others (Combination Therapy, etc.)
12.3. Market Attractiveness, by Type of Treatment
12.4. Market Value Forecast, by Type of Bladder Cancer, 2020-2034
12.4.1. Non-Muscle Invasive Bladder Cancer (NMIBC)
12.4.2. Muscle Invasive Bladder Cancer (MIBC)
12.5. Market Attractiveness, by Type of Bladder Cancer
12.6. Market Value Forecast, by Route of Administration, 2020-2034
12.6.1. Oral
12.6.2. Intravenous
12.6.3. Intravesical
12.7. Market Attractiveness, by Route of Administration
12.8. Market Value Forecast, by End-user, 2020-2034
12.8.1. Hospitals
12.8.2. Specialty Clinics
12.8.3. Ambulatory Surgical Centers
12.8.4. Cancer Research Institutes
12.9. Market Attractiveness, by End-user
12.10. Market Value Forecast, by Country/Sub-region, 2020-2034
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Market Attractiveness Analysis
12.11.1. By Type of Treatment
12.11.2. By Type of Bladder Cancer
12.11.3. By Route of Administration
12.11.4. By End-user
12.11.5. By Country/Sub-region
13. Asia Pacific Bladder Cancer Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Type of Treatment, 2020-2034
13.2.1. Chemotherapy
13.2.2. Immunotherapy
13.2.3. Targeted Therapy
13.2.4. Surgery
13.2.5. Radiation Therapy
13.2.6. Others (Combination Therapy, etc.)
13.3. Market Attractiveness, by Type of Treatment
13.4. Market Value Forecast, by Type of Bladder Cancer, 2020-2034
13.4.1. Non-Muscle Invasive Bladder Cancer (NMIBC)
13.4.2. Muscle Invasive Bladder Cancer (MIBC)
13.5. Market Attractiveness, by Type of Bladder Cancer
13.6. Market Value Forecast, by Route of Administration, 2020-2034
13.6.1. Oral
13.6.2. Intravenous
13.6.3. Intravesical
13.7. Market Attractiveness, by Route of Administration
13.8. Market Value Forecast, by End-user, 2020-2034
13.8.1. Hospitals
13.8.2. Specialty Clinics
13.8.3. Ambulatory Surgical Centers
13.8.4. Cancer Research Institutes
13.9. Market Attractiveness, by End-user
13.10. Market Value Forecast, by Country/Sub-region, 2020-2034
13.10.1. China
13.10.2. Japan
13.10.3. India
13.10.4. Australia & New Zealand
13.10.5. Rest of Asia Pacific
13.11. Market Attractiveness Analysis
13.11.1. By Type of Treatment
13.11.2. By Type of Bladder Cancer
13.11.3. By Route of Administration
13.11.4. By End-user
13.11.5. By Country/Sub-region
14. Latin America Bladder Cancer Therapeutics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Type of Treatment, 2020-2034
14.2.1. Chemotherapy
14.2.2. Immunotherapy
14.2.3. Targeted Therapy
14.2.4. Surgery
14.2.5. Radiation Therapy
14.2.6. Others (Combination Therapy, etc.)
14.3. Market Attractiveness, by Type of Treatment
14.4. Market Value Forecast, by Type of Bladder Cancer, 2020-2034
14.4.1. Non-Muscle Invasive Bladder Cancer (NMIBC)
14.4.2. Muscle Invasive Bladder Cancer (MIBC)
14.5. Market Attractiveness, by Type of Bladder Cancer
14.6. Market Value Forecast, by Route of Administration, 2020-2034
14.6.1. Oral
14.6.2. Intravenous
14.6.3. Intravesical
14.7. Market Attractiveness, by Route of Administration
14.8. Market Value Forecast, by End-user, 2020-2034
14.8.1. Hospitals
14.8.2. Specialty Clinics
14.8.3. Ambulatory Surgical Centers
14.8.4. Cancer Research Institutes
14.9. Market Attractiveness, by End-user
14.10. Market Value Forecast, by Country/Sub-region, 2020-2034
14.10.1. Brazil
14.10.2. Mexico
14.10.3. Rest of Latin America
14.11. Market Attractiveness Analysis
14.11.1. By Type of Treatment
14.11.2. By Type of Bladder Cancer
14.11.3. By Route of Administration
14.11.4. By End-user
14.11.5. By Country/Sub-region
15. Middle East & Africa Bladder Cancer Therapeutics Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Type of Treatment, 2020-2034
15.2.1. Chemotherapy
15.2.2. Immunotherapy
15.2.3. Targeted Therapy
15.2.4. Surgery
15.2.5. Radiation Therapy
15.2.6. Others (Combination Therapy, etc.)
15.3. Market Attractiveness, by Type of Treatment
15.4. Market Value Forecast, by Type of Bladder Cancer, 2020-2034
15.4.1. Non-Muscle Invasive Bladder Cancer (NMIBC)
15.4.2. Muscle Invasive Bladder Cancer (MIBC)
15.5. Market Attractiveness, by Type of Bladder Cancer
15.6. Market Value Forecast, by Route of Administration, 2020-2034
15.6.1. Oral
15.6.2. Intravenous
15.6.3. Intravesical
15.7. Market Attractiveness, by Route of Administration
15.8. Market Value Forecast, by End-user, 2020-2034
15.8.1. Hospitals
15.8.2. Specialty Clinics
15.8.3. Ambulatory Surgical Centers
15.8.4. Cancer Research Institutes
15.9. Market Attractiveness, by End-user
15.10. Market Value Forecast, by Country/Sub-region, 2020-2034
15.10.1. GCC Countries
15.10.2. South Africa
15.10.3. Rest of Middle East & Africa
15.11. Market Attractiveness Analysis
15.11.1. By Type of Treatment
15.11.2. By Type of Bladder Cancer
15.11.3. By Route of Administration
15.11.4. By End-user
15.11.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2023)
16.3. Company Profiles
16.3.1. Merck & Co., Inc.
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Bristol-Myers Squibb Company
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. F. Hoffmann-La Roche AG
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. AstraZeneca
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Johnson & Johnson
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. Pfizer Inc.
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Novartis AG
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Eli Lilly and Company
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Sanofi S.A.
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. Genentech, Inc.
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
